Centiva Capital’s Immuneering IMRX Stock Holding History

Centiva Capital’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-45,811	Closed	-$58.6K	–	2369
2024 Q2	$58.6K	Buy	+45,811	New	+$75.3K	﹤0.01%	1907

Other funds holding IMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Centiva Capital's IMRX Position: Q3 2024 in Review

Centiva Capital sold out of Immuneering (IMRX) in Q3 2024, closing a stake of 45,811 shares — an estimated $58.6K sold.

Centiva Capital first reported a position in IMRX in Q2 2024 and held it in 1 quarter. The position peaked at $58.6K in Q2 2024. 38 funds tracked by Wall St. Rank hold IMRX as of Q3 2024.

Centiva Capital reported no remaining Immuneering position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 45,811 Immuneering shares in Q3 2024, an estimated $58.6K.
Centiva Capital first reported a position in Immuneering in Q2 2024 and held it in 1 quarter.
Centiva Capital's Immuneering position peaked at $58.6K in Q2 2024.
38 funds tracked by Wall St. Rank held Immuneering as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.